News | October 01, 2010

Bioresorbable Stent Company Raises $8.5 Million


October 1, 2010 – The maker of a biodegradable stent has brought in $8.5 million during a new round of venture financing from existing investors. Arterial Remodeling Technologies (ART) now has $17 million in total investment from Matignon Technologies, Amundi Private Equity Funds and InnoBio Fund managed by CDC Enterprises.

"ART has made very significant progress over the past 22 months, and this new cash infusion will accelerate the development of our breakthrough approach of simultaneously balancing biocompatibility, biomechanics, and bioresorption within a bioresorbable PLA (polylactic acid) stent," said Machiel van der Leest, CEO.

In May 2010, ART disclosed the results of an in vivo study of 48 porcine arteries implanted with its biodegradable stent. The study demonstrated that the stent’s biodegradation is measurable and begins at the first day of implant, and it retains high radial strength, thus maintaining its structural integrity during biodegradation. Additionally, the stent causes virtually no inflammation.

"Our disruptive technology for fully resorbable coronary stents is designed to promote natural remodeling of an injured artery after angioplasty,” van der Leest said.

Earlier this year, validating data regarding ART's bioresorbable stent was published in the January 2010 special supplement of EuroIntervention, a peer-reviewed journal. The paper was authored by Antoine Lafont, M.D., Ph.D., head of Interventional Cardiology Department, Georges Pompidou Hospital (Paris), past chairman, Interventional Cardiology Group, European Society of Cardiology (ESC).

ART's bioresorbable stent is designed to be delivered by conventional stenting techniques, is balloon-expandable and meets the market standard of 6-French compatibility. ART's biopolymers have been developed in conjunction with one of the world's leading authorities in polymer chemistry, Professor Michel Vert, who is former director of the Research Center for Artificial Biopolymers at France's National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS).

For more information: www.art-stent.com


Related Content

News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
Subscribe Now